HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Otros idiomas Hansoh Pharmaceutical Group Company Limited

Acciones

3692

KYG549581067

Farmacéuticos

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:36 10/07/2026			Variación 5 días	Varia. 1 de enero.
31,94 ^HKD	+2,50 %		-5,22 %	-11,47 %

10/07	Hansoh Pharmaceutical Group Company Limited presenta resultados positivos de fase III para risvutatug rezetecan en cáncer de pulmón microcítico	CI
10/07	El fármaco oncológico de GSK y Hansoh alcanza su objetivo principal de supervivencia en un ensayo en China	RE

Otros idiomas

10/07	Hansoh Pharmaceutical Group Company Limited Reports Positive Phase III Results For Risvutatug Rezetecan In Small-Cell Lung Cancer
10/07	GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
10/07	GSK Licensor Hansoh Reports Positive Phase 3 Results for Risvutatug Rezetecan in China
10/07	Hansoh Pharmaceutical : PHARMA ANNOUNCES ARTEMIS-008 TRIAL OF RISVUTATUG REZETECAN (HS-20093) MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
07/07	Weight-loss drug developers line up to tap lucrative market as competition heats up
02/07	Hansoh Pharma Gets China Nod for Trials of Drug for Diabetes, Weight Management
02/07	Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approvals for HS-20136-2 Injection
30/06	Can Hansoh Pharmaceutical Monetize Its Expanding Drug Portfolio?
18/06	Hansoh Pharmaceutical : ESMO TAT ASIA 2026 \| HANSOH PHARMA PRESENTS PHASE 2 DATA OF RISVUTATUG REZETECAN (RIS-REZ) IN RELAPSED OR REFRACTORY SARCOMAS
18/06	Hansoh Pharmaceutical : ESMO TAT ASIA 2026 \| HANSOH PHARMA PRESENTED PHASE I DATA OF HS-20117, AN EGFR/C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH EGFR EXON 20 INSERTION-MUTATED ADVANCED NSCLC
18/06	Hansoh Pharmaceutical : PIVOTAL TRIAL OF AMEILE® PLUS CHEMOTHERAPY (AENEAS2) PUBLISHED IN THE LANCET ONCOLOGY
12/06	EHA 2026 \| HANSOH PHARMA PRESENTED DATA FROM TWO CLINICALSTUDIES OF HS-10382, A NOVEL BCR::ABL1 ALLOSTERIC INHIBITOR, IN CHRONIC MYELOID LEUKEMIA (CML)
11/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
10/06	Hansoh Pharmaceutical's Application for HS-10568 Injection Accepted in China
10/06	Hansoh Pharmaceutical Group Company Limited Announces Acceptance of New Drug Application for Hs-10568 Injection by National Medical Products Administration
10/06	Hansoh Pharmaceutical Group Company Limited Announces Change of Joint Company Secretary, with Effect from June 10, 2026
09/06	Weight-loss drug developers line up to tap lucrative market as competition heats up
08/06	Hansoh Pharmaceutical Group Company Limited(SEHK:3692) added to Hang Seng China Enterprises Index
04/06	Hansoh Pharmaceutical Group Company Limited Announces Acceptance of New Drug Application for Olatorepatide Injection
04/06	Hansoh Pharmaceutical's Weight-loss Injection Enters China Review
28/05	Higher Crude, Persian Gulf Outlooks Lowers Asian Stock Markets
22/05	Hansoh Pharma Clinches NMPA Breakthrough Designation for Fourth-Gen Cancer Tablet
21/05	Hansoh Pharmaceutical Group Company Limited Announces Breakthrough-Therapy-Designated Drug For Fourth-Generation Egfr-Tki Hs-10504 Tablets For Nsclc
15/05	Hansoh Pharmaceutical Group Company Limited Announces Changes of Joint Company Secretary with Effect from May 15, 2026
15/05	Hansoh Pharmaceutical : SID 2026 \| HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS